Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07303725

Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology

This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

VA Palo Alto Healthcare System

Palo Alto, California, 94304, United States

Location status: Recruiting

Location contact

Luisa Manfredi, MPH

CONTACT

[email protected]

650-493-5000 ext. 61706

Sirish Kishore, MD

CONTACT

[email protected]

650-493-5000 ext. 68739

Sirish Kishore, MD

PRINCIPAL_INVESTIGATOR

About this study

The aims of this study are:

  • Demonstrate the feasibility of acquisition and image quality of intra-arterial spectral CT images obtained during mapping arteriography prior to trans arterial radioembolization (TARE) for liver cancer treatment.
  • Assess the procedural utility of Spectral CT images as part of the TARE workflow, such as hepatopulmonary shunt fraction estimation, lesion identification, prediction of tumor: normal liver (T:N) dose ratio, and dose distribution
  • Investigate the feasibility, safety, and image quality of Spectral CT images obtained during tumor ablation.
  • Explore the feasibility of assessing physiologic tissue changes using Spectral CT (effective anatomic number maps)
  • During ablation with microwave, cryoablation, and irreversible electroporation in an ex vivo model
  • For image-guided tumor ablation, such as lesion identification, probe placement, and ablation monitoring.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > or = 18 years
  • Tumor in an area without prior surgical or ablative therapy
  • At least 1 tumor greater than 1.5 cm in greatest diameter

Exclusion criteria

  • Not eligible for indicated procedure.
  • BMI > 35
  • Prior surgery.

Treatment and study plan

Primary outcomes

  1. CT image

    Time frame: Baseline

    Effective Dose and CTDI

Secondary outcomes

  1. number

    Time frame: Baseline

    Number of spectral CT acquisitions per patient

  2. time

    Time frame: Baseline

    Fluoroscopy Time

Study contacts

Contact information is provided by the study sponsor or research team.

Luisa Manfredi, MPH

CONTACT

[email protected]

650-493-5000 ext. 61706

Sirish Kishore, MD

CONTACT

[email protected]

650-493-5000 ext. 61706

Sponsors and collaborators

Lead sponsor

Palo Alto Veterans Institute for Research

Other

Collaborators

  • Canon Medical Systems, USA

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 26, 2025
Registry last updated
Dec 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.